Format
Sort by
Items per page

Send to

Choose Destination

Best matches for IBRUTINIB/TU:

Ibrutinib: A Review in Chronic Lymphocytic Leukaemia. Deeks ED et al. Drugs. (2017)

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Miklos D et al. Blood. (2017)

Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. Shatzel JJ et al. J Thromb Haemost. (2017)

Search results

Items: 1 to 20 of 935

1.

Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).

Feng Y, Duan W, Cu X, Liang C, Minhang X.

Expert Opin Ther Pat. 2019 Mar 19. doi: 10.1080/13543776.2019.1594777. [Epub ahead of print]

PMID:
30888232
2.

Changes in immunosuppressive treatment of chronic graft-versus-host disease - comparison of 2 surveys within allogeneic hematopoietic stem cell transplant centers in Germany, Austria and Switzerland.

Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H.

Biol Blood Marrow Transplant. 2019 Mar 12. pii: S1083-8791(19)30154-5. doi: 10.1016/j.bbmt.2019.03.003. [Epub ahead of print]

PMID:
30876928
3.

p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.

Patrussi L, Capitani N, Ulivieri C, Manganaro N, Granai M, Cattaneo F, Kabanova A, Mundo L, Gobessi S, Frezzato F, Visentin A, Finetti F, Pelicci PG, D'Elios MM, Trentin L, Semenzato G, Leoncini L, Efremov DG, Baldari CT.

Haematologica. 2019 Feb 28. pii: haematol.2018.209981. doi: 10.3324/haematol.2018.209981. [Epub ahead of print]

4.

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.

He Y, Li J, Ding N, Wang X, Deng L, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Song Y, Zhu J.

J Exp Clin Cancer Res. 2019 Feb 18;38(1):86. doi: 10.1186/s13046-019-1076-4.

5.

Targeting thioredoxin reductase by ibrutinib promotes apoptosis of SMMC-7721 cells.

Han X, Zhang J, Shi D, Wu Y, Liu R, Liu T, Xu J, Yao X, Fang J.

J Pharmacol Exp Ther. 2019 Feb 13. pii: jpet.118.254862. doi: 10.1124/jpet.118.254862. [Epub ahead of print]

6.

Mantle cell lymphoma and its management: where are we now?

Ladha A, Zhao J, Epner EM, Pu JJ.

Exp Hematol Oncol. 2019 Jan 30;8:2. doi: 10.1186/s40164-019-0126-0. eCollection 2019. Review.

7.

Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.

Ahmed M, Lorence E, Wang J, Jung D, Zhang L, Nomie K, Wang M.

Sci Signal. 2019 Feb 5;12(567). pii: eaat4105. doi: 10.1126/scisignal.aat4105. Review.

PMID:
30723172
8.

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH.

Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.

PMID:
30709431
9.

Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.

Shi Y, Wang G, Muhowski EM, McCaw L, Wang C, Bjarnason G, Woyach JA, Spaner DE.

Leukemia. 2019 Jan 29. doi: 10.1038/s41375-019-0381-4. [Epub ahead of print]

PMID:
30696950
10.

Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.

Kahl BS, Dreyling M, Gordon LI, Martin P, Quintanilla-Martinez L, Sotomayor EM.

Leuk Lymphoma. 2019 Jan 30:1-13. doi: 10.1080/10428194.2019.1571205. [Epub ahead of print]

PMID:
30696305
11.

The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.

Lee DH, Kim GW, Kwon SH.

Mol Carcinog. 2019 Jan 29. doi: 10.1002/mc.22983. [Epub ahead of print]

PMID:
30693983
12.

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.

Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, Krall N, Pemovska T, Araghi M, Snijder B, Hubmann R, Ringler A, Runggatscher K, Demirtas D, de la Fuente OL, Hilgarth M, Skrabs C, Porpaczy E, Gruber M, Hoermann G, Kubicek S, Staber PB, Shehata M, Superti-Furga G, Jäger U, Bock C.

Nat Chem Biol. 2019 Mar;15(3):232-240. doi: 10.1038/s41589-018-0205-2. Epub 2019 Jan 28.

PMID:
30692684
13.

Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.

Denzinger V, Busygina K, Jamasbi J, Pekrul I, Spannagl M, Weber C, Lorenz R, Siess W.

Thromb Haemost. 2019 Mar;119(3):397-406. doi: 10.1055/s-0039-1677744. Epub 2019 Jan 27.

PMID:
30685871
14.

In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.

[No authors listed]

Med Lett Drugs Ther. 2018 Nov 5;60(1559):e184. No abstract available.

PMID:
30681658
15.

Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats.

Paul D, Chandrakala P, Surendran S, Bitla P, Satheeshkumar N.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Feb 15;1108:25-31. doi: 10.1016/j.jchromb.2019.01.003. Epub 2019 Jan 6.

PMID:
30660839
16.

How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Stephens DM, Byrd JC.

Blood. 2019 Mar 21;133(12):1298-1307. doi: 10.1182/blood-2018-11-846808. Epub 2019 Jan 14. Review.

PMID:
30642919
17.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
18.

Acalabrutinib for adults with mantle cell lymphoma.

Jurczak W, Długosz-Danecka M, Wang M.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):179-187. doi: 10.1080/17512433.2019.1568868. Epub 2019 Jan 26. Review.

PMID:
30638402
19.

Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.

Tobinai K, Uchida T, Fukuhara N, Nishikawa T.

Int J Hematol. 2019 Mar;109(3):366-368. doi: 10.1007/s12185-018-02577-8. Epub 2019 Jan 8. No abstract available.

PMID:
30623356
20.

Lenalidomide for the treatment of mantle cell lymphoma.

Morabito F, Skafi M, Recchia AG, Kashkeesh A, Hindiyeh M, Sabatleen A, Morabito L, Alijanazreh H, Hamamreh Y, Gentile M.

Expert Opin Pharmacother. 2019 Apr;20(5):487-494. doi: 10.1080/14656566.2018.1561865. Epub 2019 Jan 4.

PMID:
30608891

Supplemental Content

Loading ...
Support Center